Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, et al. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016;30(12):2402-2405.

Huong G, Olson LC, Rippis GE, Magro CM. An Index Case of Cutaneous Hodgkin Lymphoma and Review of the Literature. Am J Dermatopathol. 2016;38(10):739-43.

Goyal A, Abdul-Karim FW, Yang B, Patel JB, Brainard JA. Interobserver agreement in the cytologic grading of atypia in neoplastic pancreatic mucinous cysts with the 2-tiered approach. Cancer Cytopathol. 2016;124(12):909-916.

Jain T, Williams R, Liechty B, Chen LA. Vertebral Metastasis as the Initial Manifestation of Colon Cancer. ACG Case Rep J. 2016;3(4):e122.

Rudman SM, Gray KP, Batista JL, Pitt MJ, Giovannucci EL, Harper PG, et al. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016;118(6):919-926.

Jain M, Robinson BD, Aggarwal A, Shevchuk MM, Scherr DS, Mukherjee S. Multiphoton microscopy for rapid histopathological evaluation of kidney tumours. BJU Int. 2016;118(1):118-26.

Olson LC, Cheng E, Mathew S, Torres-Quinones M, Magro C. Primary Cutaneous Anaplastic Large-Cell Lymphoma With 6p25.3 Rearrangement in a Cardiac Transplant Recipient: A Case Report and Review of the Literature. Am J Dermatopathol. 2016;38(6):461-5.

Pal S, Graves H, Ohsawa R, Huang T-, Wang P, Harmacek L, et al. The Commercial Antibodies Widely Used to Measure H3 K56 Acetylation Are Non-Specific in Human and Drosophila Cells. PLoS One. 2016;11(5):e0155409.

Onur I, Siddiqui MT, Wakely PE, Ali SZ. Pseudomyxoma peritonei: cytomorphologic findings and clinicopathologic correlates. J Am Soc Cytopathol. 2016;5(1):43-49.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, et al. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 2016;7(48):79637-79653.